Repligen Corporation Q3 2026 Earnings Recap

Repligen’s shares fell 2.4% after earnings, a roughly flat reaction. The quarter showed solid organic growth and margin expansion, while the key constraint remains capital equipment: revenue declined despite a mid-teens increase in orders, and management said demand has not opened up as quickly as expected.

Key Takeaways

• Q3 revenue was $209 million, up 12.5% organically; adjusted operating margin expanded 170 basis points year over year.
• Consumables grew 20% and services grew more than 20%. Capital equipment orders rose mid-teens and reached a five-year quarterly high, but revenue declined.
• Management narrowed its full-year organic growth outlook to 12%–13%, with the midpoint up 50 basis points; updated guidance includes $24 million of BioLife revenue after the Q4 close.
• Biopharma growth was strong across regions, while CDMO revenue declined against a difficult comparison. New modalities were relatively flat, with cell therapy up nearly 30%.
• Services were 7% of quarterly revenue; systems under service contract increased nearly 40% year to date.